5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | NEUTRAL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.68▲ | 0.68▲ | 0.68▲ | 0.70▼ | 0.72▼ |
MA10 | 0.68▲ | 0.68▲ | 0.68▲ | 0.72▼ | 0.91▼ |
MA20 | 0.68▲ | 0.68▲ | 0.69▲ | 0.74▼ | 1.32▼ |
MA50 | 0.69▲ | 0.69▲ | 0.71▼ | 0.97▼ | 2.06▼ |
MA100 | 0.70▼ | 0.71▼ | 0.73▼ | 1.40▼ | 2.54▼ |
MA200 | 0.72▼ | 0.74▼ | 0.82▼ | 2.00▼ | 3.16▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.001▲ | 0.001▲ | 0.013▲ | -0.044▼ |
RSI | 56.787▲ | 52.466▲ | 49.576▼ | 38.462▼ | 23.768▼ |
STOCH | 63.119 | 40.024 | 24.669 | 17.494▼ | 5.118▼ |
WILL %R | -3.529▲ | -36.187 | -72.712 | -87.939▼ | -98.092▼ |
CCI | 136.313▲ | 101.680▲ | 35.066 | -107.512▼ | -89.444 |
Wednesday, April 30, 2025 05:16 AM
Q1 2025 Earnings Call Transcript April 29, 2025 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.14. Operator: Good day, and thank you for ...
|
Wednesday, April 30, 2025 12:10 AM
Nautilus Biotechnology Inc (NAUT) reports a 13% decrease in operating expenses and maintains a robust cash runway through 2027, while advancing its proteoform assay development.
|
Tuesday, April 29, 2025 10:01 AM
Discover Nautilus Biotechnology's Q1 2025 progress in proteome analysis, including tau proteoform assay readiness, partnership plans, and a steady ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 0.691 | 0.699 | 0.67 | 0.6849 | 121,761 |
30/04/25 | 0.71 | 0.71 | 0.675 | 0.6886 | 198,018 |
29/04/25 | 0.7172 | 0.7342 | 0.6825 | 0.7342 | 188,919 |
28/04/25 | 0.72 | 0.72 | 0.67 | 0.68 | 312,072 |
25/04/25 | 0.7044 | 0.7119 | 0.665 | 0.6884 | 276,295 |
24/04/25 | 0.7444 | 0.7444 | 0.70 | 0.713 | 227,862 |
23/04/25 | 0.7988 | 0.8222 | 0.7101 | 0.7421 | 260,689 |
22/04/25 | 0.7403 | 0.7848 | 0.72 | 0.782 | 134,637 |
21/04/25 | 0.77 | 0.77 | 0.707 | 0.72 | 154,441 |
17/04/25 | 0.72 | 0.82 | 0.72 | 0.758 | 88,114 |
|
|
||||
|
|
||||
|
|